Aspira Women's Health Files S-1
Ticker: AWHL · Form: S-1 · Filed: Jan 8, 2025 · CIK: 926617
Sentiment: neutral
Topics: s-1, registration-statement, healthcare
TL;DR
Aspira Women's Health filed an S-1, looks like they're raising cash.
AI Summary
Aspira Women's Health Inc. filed an S-1 registration statement on January 8, 2025, to register securities under the Securities Act of 1933. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas. The filing indicates a potential offering of securities, though specific dollar amounts and dates for the offering are not detailed in this excerpt.
Why It Matters
This S-1 filing signals Aspira Women's Health Inc.'s intent to raise capital through a public offering, which could impact its future growth and operations.
Risk Assessment
Risk Level: medium — S-1 filings often precede significant corporate actions like stock offerings, which carry inherent market risks.
Key Numbers
- 333-284182 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 2835 — SIC Code (Indicates the company operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry.)
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- January 8, 2025 (date) — Filing Date
- Securities Act of 1933 (legal_document) — Governing Act
- Vermillion, Inc. (company) — Former Company Name
- Ciphergen Biosystems Inc (company) — Former Company Name
- Abiotic Systems (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Austin, Texas (location) — Principal Executive Offices
- Sandra Milligan (person) — Interim Chief Executive Officer
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement filed with the SEC to register securities for a potential public offering under the Securities Act of 1933.
When was this S-1 filing submitted?
The filing was submitted on January 8, 2025.
What are some of Aspira Women's Health Inc.'s former company names?
Aspira Women's Health Inc. was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.
Where is Aspira Women's Health Inc. headquartered?
The company's principal executive offices are located at 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738.
Who is the Interim Chief Executive Officer of Aspira Women's Health Inc.?
Sandra Milligan is the Interim Chief Executive Officer.
Filing Stats: 4,260 words · 17 min read · ~14 pages · Grade level 18 · Accepted 2025-01-08 17:30:32
Key Financial Figures
- $0.75 — at an assumed public offering price of $0.75 per share, the last reported sale price
- $0.001 — ck, exercisable at an exercise price of $0.001 per share, to those purchasers whose pu
Filing Documents
- forms-1.htm (S-1) — 852KB
- ex5-1.htm (EX-5.1) — 27KB
- ex23-1.htm (EX-23.1) — 4KB
- ex107.htm (EX-FILING FEES) — 51KB
- forms-1_001.jpg (GRAPHIC) — 28KB
- ex5-1_001.jpg (GRAPHIC) — 15KB
- as_001.jpg (GRAPHIC) — 9KB
- 0001493152-25-001451.txt ( ) — 1006KB
Underwriting
Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the public offering price payable to the representative of the underwriters. See “Underwriting” beginning on page 38 for additional information regarding underwriters’ compensation. We have granted a 45-day option to the underwriters to purchase up to 2,400,000 additional shares of common stock and/or up to 2,400,000 Pre-funded Warrants solely to cover over-allotments, if any. The underwriters expect to deliver the securities to purchasers on or about , 2025. ThinkEquity The date of this prospectus is , 2025 TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 INFORMATION REGARDING FORWARD-LOOKING STATEMENTS 2 PROSPECTUS SUMMARY 5 THE OFFERING 11 RISK FACTORS 13 USE OF PROCEEDS 16
DILUTION
DILUTION 17 MANAGEMENT 19 EXECUTIVE AND DIRECTOR COMPENSATION 22 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 32 PRINCIPAL STOCKHOLDERS 33 DESCRIPTION OF SECURITIES WE ARE OFFERING 34
UNDERWRITING
UNDERWRITING 38 LEGAL MATTERS 43 EXPERTS 43 WHERE YOU CAN FIND MORE INFORMATION 43 INCORPORATION OF DOCUMENTS BY REFERENCE 44 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Documents by Reference” before deciding to invest in our securities. Neither we nor the underwriters have authorized anyone to provide you with additional information or information different from that contained or incorporated by reference in this prospectus filed with the Securities and Exchange Commission (the “SEC”). We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The underwriters are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimat